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A new cell-based AI-2-mediated quorum sensing interference 
assay in screening of LsrK-targeted inhibitors 
Viviana Gatta[a], Tihomir Tomašič[b], Janez Ilaš[b], Nace Zidar[b], Lucija Peterlin Mašič[b], Michaela 
Barančoková[b], Rok Frlan[b], Marko Anderluh[b], Danijel Kikelj[b], Päivi Tammela*[a] 
Abstract: Quorum sensing (QS), a bacterial communication strategy, 
has been recognized as one of the control mechanisms of virulence 
in bacteria. Thus, targeting QS offers an interesting opportunity to 
impair bacterial pathogenicity and develop antivirulence agents. 
Aiming to enhance the discovery of QS inhibitors, we developed a 
bioreporter E. coli JW5505 pET-Plsrlux and set up a cell-based assay 
for identifying inhibitors of autoinducer-2 (AI-2) -mediated QS. A 
comparative study on the performance of target-based and cell-based 
assay was performed. 91 compounds selected with the potential to 
target the ATP binding pocket of LsrK, a key enzyme in AI-2 
processing, were tested in a LsrK inhibition assay providing 36 hits. 
The same set of compounds was tested by the AI-2-mediated QS 
interference assay resulting in 24 active compounds. Among those, 6 
compounds were also active against LsrK whereas 18 may target 
other components of the pathway. Thus, the AI-2-mediated QS 
interference cell-based assay is an effective tool for complementing 
target-based assays but also as independent assay for primary 
screening. 
Introduction 
Bacterial infections are one the biggest threats to human health. 
[1 ] In fact, spontaneous mutations, combined with the general 
misuse of antibiotics, have now compromised the efficacy many 
antibiotics, exposing humans to multidrug-resistant bacteria. [2,3,4] 
Traditional antibiotics are bactericidal or bacteriostatic, targeting 
essential cellular functions which are related to bacterial growth 
and survival. This leads to selection of resistant bacterial 
subpopulations, which become the dominant population. 
However, the concept that infection is not just the result of the 
presence of pathogens but it rather depends on host-
microorganism interactions is now prevailing, broadening the 
typology and availability of targets addressed in the development 
of new treatments. [5] Since virulence is the capacity of bacteria to 
attack the host by activating several mechanisms known as 
virulence factors, interfering with virulence aims to disarm the 
pathogens which could be then cleared by the host immune 
system, lowering the emergence of resistance. [6, 7, 8] 
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Several antivirulence agents have been reported, targeting 
different processes such as toxin neutralization [, biofilm 
formation, and motility. [9 , 10 , 11 , 12 , 13 ] However, these bacterial 
responses are finely regulated and very often controlled by a 
sophisticated process called quorum sensing (QS). [14,15,16] QS is 
a bacterial communication strategy, mediated by release and 
recognition of small molecules called autoinducers which are 
processed intracellularly to activate several genes involved in 
virulence factor production. [17] Targeting QS offers a strategy to 
alter bacterial gene expression, impairing simultaneously several 
aspects which contribute to virulence and infection. Although 
several QS pathways have been characterized, autoinducer-2 
(AI-2) -mediated QS remains one of the most significant. (S)-4,5-
dihydroxy-2,3-pentanedione (DPD), the precursor of AI-2, is in 
fact recognized and processed by both Gram-positive and -
negative bacteria. [18] In enteric bacteria, lsr operon encodes for 
the Lsr transporter together with the Lsr kinase (LsrK) and the Lsr 
repressor (LsrR). AI-2 is internalized by lsr transporter and 
phosphorylated by LsrK. The phosphorylated form of AI-2 is able 
to bind the Lsr repressor (LsrR) enhancing the transcription of the 
lsr operon and the activation of the QS cascade. Since 
phosphorylation is the essential step for displacing the repressor 
and the activation of the pathway, LsrK has been investigated as 
potential target for QS inhibition with promising results. Indeed, 
small sets of compounds have been previously investigated 
against LsrK to estimate the effect of DPD modifications on the 
AI-2-mediated QS pathway and LsrK inhibitors have been 
identified. [19, 20, 21 ,22,23] However, the activity of these inhibitors in 
cell-based assay have been rarely reported. [22, 23 ] Previously 
described cell-based assays to evaluate inhibitory effect of 
compounds on AI-2-mediated QS are based on β-galactosidase 
activity controlled by lsr promoter. The addition of DPD activates 
the lsr transcription leading to β-galactosidase production which 
can be then quantified by monitoring the formation of the colored 
reaction product, after addition of the substrate, ortho-nitrophenyl-
β-galactoside (ONPG). [ 24 , 25 ] However, the need of several steps 
such as cell lysis and addition of a detection mixture, including the 
substrates and co-factors necessary for β-gal reaction, makes the 
process time-consuming and difficult to automate. Additionally, 
the sensitivity of absorbance-based assay is quite low and the 
read-out can be affected by compounds absorbing at 420 nm, 
used for quantifying the final product. A bioreporter strain for the 
evaluation of AI-2-mediated QS inhibitors based on the 
toxin/antitoxin system has also been reported. [26] In the construct 
the lethal gene ccdB is under control of QS responsive promoter 
and thus, if QS is activated, the protein is expressed causing the 
death of the cell whereas QS inhibitors would prevent ccdB 
transcription, resulting in a viable cell. However, toxic compounds 
may affect the results, thus an additional control strain is needed. 
Both assays require addition of external DPD to activate the 
pathway and, although this may offer a better control on the 
system, it also increases the cost and creates artificial conditions. 
In this study, we developed a fast, sensitive and simple cell-based 
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on luminescence. Using this assay, we performed screening of a 
91-compound library, originally designed as gyrase B inhibitors 
targeting its ATP binding site [26] and thus endowed with 
capability to target also LsrK ATP binding pocket. The screening 
against LsrK in target-based functional assay led to the 
identification of 29 active compounds, with an IC50 ranging from 8 
to 147 µM. Among those, 6 showed activity in the bioreporter 
strain, impairing the response to QS as result of LsrK inhibition. 
Additionally, 18 compounds, which did not display any activity 
against LsrK, were found active in the bioreporter strain, as result 
of the inhibition of other components of the pathway, proving the 
effectiveness of our bioreporter strain as a new tool for discovery 
of QS inhibitors. 
Results and Discussion 
Screening against LsrK 
Compound library synthetized as ATP-competitive gyrase B 
inhibitors, was used as a starting point. This library contained 
more than 800 compounds out of which 91 structurally diverse 
compounds were selected visually to cover the whole chemical 
space of the library and were tested against LsrK at 100 µM using 
a kinase inhibition assay. [27] Compounds showing an inhibition ≥ 
70 % were selected for dose-response experiments (Table 1, 
Figure S1).  
 
 
Table 1. IC50 values for the 29 positive 
hits selected by primary screening 
against LsrK. Data points represent 
means ± SD from two independent 
experiments (n=4). 
Compound IC50 (µM) 
UL-01 26 ± 1 
UL-02 76 ± 6 
UL-03 28± 3 
UL-04 17± 2 
UL-05 18± 2 
UL-06 147±12 
UL-07 54± 2 
UL-09 78± 1 
UL-10 63± 11 
UL-11 36 ± 5 
UL-12 33 ± 3 
UL-13 18 ± 1 
UL-14 32 ± 2 
UL-15 11 ± 0.1 
UL-16 40 ± 2 
UL-17 8 ± 1 
UL-18 39 ± 2 
UL-19 29 ± 2 
UL-20 83 ± 8 
UL-21 15 ± 1 
UL-22 27 ± 4 
UL-23 40 ± 3 
UL-24 21 ± 2 
UL-25 45 ± 6 
UL-26 10 ± 1 
UL-27 31 ± 1 
UL-28 51 ± 4 
UL-29 59 ± 2.5 




Cell-based AI-2-mediated QS interference 
assay 
 
Previously reported cell-based AI-2-mediated QS interference 
assays present some limitations due to the complexity and length 
of the protocol together with low sensitivity and potential 
interference by toxic compounds. Aiming to enforce the discovery 
of antivirulence agents based on AI-2-mediated QS inhibition, we 
designed a new plasmid pET-Plsrlux which contains the bacterial 
luciferase operon luxABCDE under control of lsr, a QS responsive 
promoter, and developed a new bioreporter assay which allows 
rapid identification of QS inhibitors by luminescence detection 
technology. Thus, when AI-2-mediated QS is activated, this leads 
to lux expression and production of light whereas, in the presence 
of QS inhibitors, no light will be detected. The plasmid was 
constructed by replacing the PesaR, a QS responsive promoter 
induced by 3-oxo-hexanoyl-homoserine lactone, with the lsr 
promoter in the pET-PesaRlux plasmid  and the new construct 
was transformed into single-gene knock-out E. coli JW5503 which, 
due to efflux pump defect, is unable to expel xenobiotics from the 
cell. [28, 29] Since extrusion by the efflux pump system is one of the 
main obstacles for the discovery of new antibacterial agents and 
even limits the identification of target-active compounds to be 
further optimized, we considered the reduced efflux activity of the 
strain as an advantage to identify candidate molecules which can 
be then further optimized. The strain is able to synthetize its own 
DPD contributing to more physiological conditions, reduced cost 
and complexity of the assay. To decrease the rate of false 
positives, luminescence and turbidity to assess QS inhibition and 
cell density, respectively, can be monitored in parallel to ensure 
that the reduced luminescence results from QS inhibition is not 
due to bacterial toxicity. 
E. coli JW5503 pET-Plsrlux was grown overnight and diluted into 
fresh LB. The day of the assay bacteria were grown at 30°C until 
exponential phase and then centrifuged to remove the 
supernatant. This step is essential for the success of the assay to 
ensure the removal of the DPD produced during the incubation 
time which may otherwise interfere with the assay. To select the 
optimal bacterial inoculum for the assay, 3 concentrations were 
evaluated: 5*105 CFU/ml, 5*106 CFU/ml, 5*107 CFU/ml (Table S2). 
Due to its ability to fully repress the transcription of lsr operon, 
glucose was used as a positive control [30]. Bacteria were then 
incubated up to 7 hours, with and without 2% glucose, and 
luminescence and absorbance was measured every hour. For 
each time point signal/background (S/B) and Z´ factor, quality 
parameters commonly used to determine assay quality in 
screening assay development, were calculated to select the 
optimal conditions (Table S2). For S/B, which is defined as the 
ratio of the maximum signal to the minimum signal, values ≥ 2 
were considered acceptable whereas for Z´ values, which takes 
into account not only the averages but also their variability, values 
≥ 0.5 were pursued. [31]  
In case of lowest CFU/ml concentration acceptable S/B values 
were reached after 5 h but the Z´ factor remained ≤ 0 indicating 
high signal variability. Similar situation was observed for 5*106 
CFU/ml concentration where, despite the good separation already 
observed after 1 h incubation, the Z´ value reached an acceptable 
value of 0.5 only at 5 h, starting then to decrease. At the highest 
tested concentration, good separation was observed after 1 h 
incubation and an excellent Z´ value of 0.92 was observed at 3-h 
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possible incubation time, 5*107 CFU/ml and 3h incubation were 
selected as optimal assay conditions. Additionally, the Z´ factor 
remained acceptable up to 7 hours, ensuring the high stability of 
the assay. 
DMSO tolerance of the assay was also evaluated. At 
concentrations above 2% DMSO significantly inhibits the 
luminescence and, at concentrations ≥ 4%, it also dramatically 
affects the growth, thus DMSO concentrations were kept below 
2% in the experiments (Figure S2). 
 
 
Screening against E. coli JW5503 pET-Plsrlux 
 
The set of 91 compounds was tested against E. coli JW5503 pET-
Plsrlux to verify the activity of the positive hits against LsrK in 
cellular context and to evaluate simultaneously the potential of the 
compounds to affect other targets involved in the same pathway.  
74 among 91 compounds showed QS inhibition ≥ 50%. Inhibition 
of growth was evaluated in parallel to ensure that the reduced 
luminescence is the result of QS inhibition and not due to 
compound toxicity or antibacterial activity. Indeed, among the 74 
active compounds, 44 showed a growth inhibition ≥40 %, thus the 
observed decrease of the luminescence was consequence of 
bacterial death (Table S3).  
Combined analysis of QS inhibition and growth inhibition led to 
the selection of 24 compounds with QS inhibition ≥ 80% and 




Table 2. IC50 values for QS 
inhibition for the positive hits 
selected by primary screening on 
E. coli JW5503 pET-Plsrlux. Data 
points represent means ± SD from 
two independent experiments 
(n=3). 
Compound IC50 (µM) 
UL-87 34 ± 12 
UL-54 45 ± 4 
UL-31 12 ± 1 
UL-81 24± 3 
UL-32 7± 0.2  
UL-41 53± 8 
UL-19 1± 0.1  
UL-03 0.6± 0.1 
UL-21 0.4 ±0.2  
UL-36 2± 0.7  
UL-05 10± 0.4 
UL-67 2± 0.2 
UL-55 34± 0.5  
UL-53 31± 1 
UL-69 0.6± 0.1 
UL-73 30 ±1 
UL-48 96± 2  
UL-76 1± 0.1 
UL-09 17 ±2 
UL-78 6 ±1 
UL-90 8± 0.2  
UL-83 39± 6 
UL-84 2± 0.1 
UL-06 2 ±0.2 
 
The QS inhibition activity of UL-03, UL-05, UL-06, UL-09, UL-19 
and UL-21, which were identified as LsrK inhibitors, was 
confirmed in the cell-based assay. Moreover, the most potent 
LsrK inhibitors UL-03 and UL-21 were docked to the LsrK crystal 
structure (PDB entry: 5YA2) to predict their possible binding mode 
in the ATP-binding site.[32] Based on docking calculations both 
inhibitors can form a salt bridge with Arg319 side chain and 
several hydrophobic interactions with Tyr341, Thr342 and Trp435 
(Figure S4) in the LsrK active site. The discrepancy observed 
between the IC50 determined by cell-based assay and the IC50 
determined by target-based assay may be attributed to structural 
differences in the binding pocket region between the LsrK from S. 
typhimurium, used for the target-based assay, and the LsrK from 
E. coli, used for the cell-based assay, which may differently 
impact the interaction with small molecules. [33] UL-03 and UL-21 
were the most effective compounds with an IC50 in the 
submicromolar range (Figure 1). Additionally, 18 hits were found 
which may target other elements in the pathway such as the lsr 
transporter or repressor.  
 
Unfortunately, when tested on E. coli ATCC255922, a strain with 
regular efflux pump activity, which was transformed with the same 
construct pET-Plsrlux, the set of hits selected against E. coli 
JW5503 pET-Plsrlux did not show significant QS inhibition 






























Figure 1. Structures of hit compounds active against LsrK and in the AI-2-
mediated QS interference assay. 
Conclusions 
 
To support the discovery of new QS inhibitors, we developed a 
new AI-2-mediated QS interference assay based on the detection 
of luciferase produced in E. coli JW5503 pET-Plsrlux. The assay 
was validated by screening a library of 91 compounds originally 
designed as ATP-competitive gyrase B inhibitors endowed with 
capability to target also ATP binding pocket of LsrK, a key enzyme 
in AI-2-mediated QS. [27] The set of compounds was tested on a 
5 (KMB95) 
IC50 LsrK = 15±1 µM 
IC50 LsrK = 0.4±0.2 µM 
6 (NHM63) 
IC50 LsrK = 78±1 µM 
IC50 LsrK = 17±2 µM 
8 (NBH55) 
IC50 QS = 0.6±0.1 µM 
 
UL-05 
IC50 LsrK=18±2 µM 
IC50 QS=10±0.4 µM 
UL-06 
IC50 LsrK=147±12 µM 
IC50 QS=2.0±0.2 µM 
UL-21 
IC50 LsrK=15±1 µM 
IC50 QS=0.4±0.2 µM 
UL-09 
IC50 LsrK=78±1 µM 
IC50 QS=17±2 µM 
UL-19 
IC50 LsrK=29±2 µM 
IC50 QS=1.0±0.1 µM 
UL-03 
IC50 LsrK=18±2 µM 
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LsrK inhibition assay and on the cell-based AI-2-mediated QS 
interference assay and the obtained hits were compared. 
Six compounds, which were active against LsrK, also inhibit the 
QS activation in the cell-based assay. The cell-based AI-2-
mediated QS interference assay also provided 18 additional hits 
which did not show any activity against LsrK and may target other 
members of the lsr pathway. More in-depth study will be needed 
to identify the mode of action and a multidisciplinary effort will be 
required to understand and develop the potential of these 
molecules as precursors of a new class of antivirulence drugs. 
However, the new developed assay proved its effectiveness as 
complementary assay to confirm the activity of hits selected by 
target-based screening and as a primary tool for cell-based 
screening of compound libraries to facilitate the identification of 




E. coli MET1158 was donated by Prof. Karina Xavier (Instituto Gulbenkian 
de Ciência, Portugal). [30] E. coli LW7 pLW11 was provided by Prof. 
William Bentley (University of Meriland, USA). E. coli JW5503 and E. coli 
ATCC 25922 were obtained from the NBRP-E. coli collection at the 
National Institute of Genetics (NIG, Japan) and the American Type Culture 
Collection (ATCC) via Microbiologics Inc. (St.cloud, MN), respectively. [29] 
The plasmid pET-PesaRlux was provided by Dr. Collins (Rensselaer 
Polytechnic Institute, NY, USA) and obtained through Addgene 
(Watertown, Massachusetts, USA). [28, 34 ] 
For the enzymatic assay, DPD and Kinase-Glo Max Luminescent kinase 
assay were acquired from Carbosynth (Compton, Berkshire, UK) and 
Promega Corp. (Madison, WI, USA), respectively. 
Materials for cloning including restriction enzymes (XhoI, BamHI-HF), Q5® 
High-Fidelity PCR Kit and T4 ligase were purchased from New England 
Biolabs (Ipswich, Massachusetts, USA). Subcloning Efficiency™ DH5α™ 
Competent Cells were obtained from Thermo Fisher Scientific (Waltham, 
MA, USA). All other reagents were purchased from Sigma (USA). Plates 
were purchased from Greiner Bio One (Kremsmünster, Austria) for the 
LsrK inhibition assay, and from PerkinElmer (Waltham, MA, USA) for the 
cell-based AI-2-mediated QS interference assay. 
 
LsrK overexpression and purification 
 
LsrK from S. typhimurium was overexpressed in E. coli MET1158 [E. coli, 
amp resistance, BL21 (DE3) luxS‐ , with pMET1144 (lsrK‐ His in 
pET21b), and purified by affinity chromatography as previously described. 
[23] 
 
Primary screening against LsrK and dose-
response assay 
 
91 compounds, dissolved in DMSO, were tested at a final concentration of 
100 µM. The assay was performed with 300 nM LsrK, 100 µM ATP and 
300 µM DPD in assay buffer (25 mM TEA, pH 7.4, 200 µM MgCl2 and 0.1 
mg/ml BSA) using the Kinase-Glo Max Luminescent kinase assay as 
previously reported. [23] Positive hits selected by primary screening were 




A library of UL-03 and UL-21 conformers was generated using OMEGA 
software (Release 3.1.0.3, OpenEye Scientific Software, Inc., Santa Fe, 
NM, USA; www.eyesopen.com) using default settings. [35]  For docking with 
FRED software (Release 3.3.0.3, OpenEye Scientific Software, Inc., Santa 
Fe, NM, USA; www.eyesopen.com), LsrK ATP-binding site (PDB entry: 
5YA2) was prepared using MAKE RECEPTOR (Release 3.3.0.3, 
OpenEye Scientific Software, Inc., Santa Fe, NM, USA; 
www.eyesopen.com). [36,37, 38] The grid box around the ADP bound in the 
crystal structure was generated automatically and was not adjusted. This 
resulted in a box with the following dimensions: 16.00 Å *18.00 Å * 18.33 
Å and the volume of 5280 Å3. For “Cavity detection” slow and effective 
“Molecular” method was used for detection of binding sites. Inner and outer 
contours of the grid box were also calculated automatically using 
“Balanced” settings for “Site Shape Potential” calculation. The inner 
contours were disabled and no docking constraints were defined. The 
OMEGA-generated library of UL-03 and UL-21 conformers was then 
docked in the prepared binding site. Ten docking poses were inspected 
visually and the highest ranked docking pose was used for the 




The plasmid pLW11 containing lsr promoter was extracted from E. coli 
LW7 and used as a template for the amplification by PCR of the lsr 
promoter with the following primers: 
 
lsp_F : TATCTCGAGGCGACCTGTTCTTCTTCACACATT 
lsp_R: TATGGATCCTCGATGCCTTTCAGGACATTG 
 
The primer lspF introduced a restriction site for XhoI. The PCR product 
was digested with XhoI and BamHI and cloned into XhoI and BamHI 
digested pET-PesaRlux [28] using T4 ligase. The reaction product was 
transformed into Subcloning Efficiency™ DH5α™ Competent Cell 
according to manufacturer´s instructions and then transferred into E. coli 
JW5503 or E. coli ATCC 25922 competent cells. [39 ] E. coli JW5503 pET-
Plsrlux was grown overnight in LB supplemented with 25 µg/ml kanamycin 
and 100 µg/ml ampicillin and luminescence was measured to confirm the 
functionality of the construct by Varioskan LUX plate reader. 
 
Cell-based AI-2-mediated QS interference 
assay protocol 
 
E. coli JW5503 pET-Plsrlux was grown overnight in LB supplemented with 
25 µg/ml kanamycin and 100 µg/ml ampicillin. The following morning 
bacteria were diluted 1:100 into fresh LB supplemented with antibiotics and 
grown at 30 °C until exponential phase (2.2-3.5 McFarland unit) [24]. 
Bacteria were centrifuged at 3000xg for 10 minutes and the pellet was 
resuspended into fresh LB. A suspension containing 1*108 CFU/ml was 
prepared and 50 µl were added to the plate. 50 µl of LB for negative control 
or 50 µl of LB supplemented with 2% glucose for positive control were also 
added and the plate was incubated at 37 °C under shaking for 3 hours. 





91 compounds were tested on the bioreporter strain at final concentration 
of 100 µM. Assay was performed as described above. Luminescence and 
Abs600 were measured and compounds showing an inhibition of 
luminescence ≥80% and an inhibition of growth ≤ 40 % were selected for 
dose-response experiment. Positive hits were also tested against E. coli 




During the assay development, optimization and validation, the assay 
performance was evaluated by calculating quality parameters typically 
used in HTS, Z’ and S/B according to the following equations: [31] 
 
 Z’= 1- (3*σM+3*σm)/(|µM-µm|)                             
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In the equations µM and σM represent, respectively, the average and the 
standard deviation for the maximum signal, given by the wells containing 
only bacteria. µm and σm represent average and standard deviation for 
the minimum signal, from wells containing bacteria and 2% glucose. Good 
quality assays are indicated by Z’ factor > 0.5.  
QS and growth inhibition % for each test compound was determined 
according to the following equations: 
 
Inhibition (% ) = 100* {1- [(X-Xm)/(XM-Xm)]}                           
 
In the equation, X represents the detected luminescence or absorbance 
value from a sample, while XM and Xm are respectively the average of the 
detected luminescence or absorbance value for the maximum and 
minimum controls. 
Acknowledgements 
This study was supported by European Union’s Horizon 2020 
research and innovation program under the Marie Sklodowska-
Curie grant agreement No 642620 (INTEGRATE), by the 
Academy of Finland (Grant nos. 277001 and 312503) and by the 
Slovenian Research Agency (grant P1-0208). We also thank the 
DDCB core facility supported by the University of Helsinki, 
Biocenter Finland and OpenEye Scientific Software (Santa Fe, 
NM.) for free academic licenses for the use of their software. 
Maritta Keurulainen is thanked for her help in cloning.  
 
Conflict of interest 
 
The authors declare no conflict of interest. 
Keywords: antivirulence • Gram-negative bacteria • bioreporter 




[1] S.E. Cosgrove, Clin Infect Di. 2006, 42, S82– S89. 
 
[2] J. Davies, D. Davies, Microbiol Mol Biol Rev 2010, 74, 417–433. 
 
[3] E.J. Klemm, V.K Wong, G. Dougan, Proc Natl Acad Sci USA 2018, 115, 
12872–12877. 
 
[4] S.B. Zaman, M.A. Hussain, R. Nye, V. Mehta, K.T. Mamun, N. Hossain, 
Cureus 2017, 28, 9(6), e1403. 
 
[5] J. Munguia, V.  Nizet, Trends Pharmacol Sci, 2017, 38(5), 473-488. 
 
[6] S.W. Dickey, G.Y.C Cheung, M. Otto, Nat Rev Drug Discov 2017, 16(7), 457-
471. 
 
[7] M.B. Calvert, V.R.  Jumde, A. Titz, Beilstein J Org Chem 2018, 14, 2607-
2617.  
 
[8] C.L. Quave, J.T. Lyles, J.S. Kavanaugh, K. Nelson, C.P. Parlet, H.A. Crosby, 
K.P. Heilmann, A.R. Horswill, PLoS One 2015, 10(8), e0136486. 
 
[9] K.O. Bender, M. Garland, J.A. Ferreyra, A.J. Hryckowian, M.A. Child, A.W. 
Puri, D.E. Solow-Cordero, S.K. Higginbottom, E. Segal, N. Banaei, A. 
Shen, J.L. Sonnenburg, M. Bogyo, Sci Transl Med, 2015; 7(306), 
306ra148. 
 
[10] R.V. Ortines, H. Liu, L.I. Cheng, T.S. Cohen, H. Lawlor, A. Gami, Y. Wang, 
C.A. Dillen, N.K. Archer, R.J. Miller, A.G. Ashbaugh, B.L. Pinsker, M.C. 
Marchitto, C. Tkaczyk, C.K. Stover, B.R. Sellman, L.S. Miller, Antimicrob 
Agents Chemother 2018, 62(3), pii: 02288-17.  
 
[11] J. Ranfaing, C. Dunyach-Remy, J.P. Lavigne, A. SottO, PLoS One 2018, 
13(8), e0202609. 
 
[12] X. Feng, W. Guo, H. Zheng, J. Du, H. Luo, Q. Wu, R. Nanqui, Biochem Eng 
J 2018, 137, 95–99.  
 
[13] J. Wang, X.H. Nong, M. Amin, S.H. Qi, Appl Microbiol Biotechnol 2018, 
102(3), 1417-1427 
 
[14] S.T. Rutherford, B.L. Bassler, Cold Spring Harb Perspect Med 2012, 2(11),  
pii: a012427. 
 
[15] S.W. Dickey, G.Y.C. Cheung, M. Otto, Nat Rev Drug Discov 2017, 16(7), 
457-471.  
 
[16] T. Defoirdt, Trends Microbiol 2018, 26(4), 313-328. 
 
[17] K. Papenfort K, B.L. Bassler, Nat Rev Microbiol 2016, 14(9),576-88. 
 
[18] C.S. Pereira, J.A. Thompson, K.B. Xavier, FEMS Microbiol Rev 2013,37(2), 
156-181. 
 
[19] V. Roy, R. Fernandes, C.Y. Tsao, W.E. Bentley, ACS Chem Biol 2010; 5, 
223–232.  
 
[20] K. Tsuchikama, J. Zhu , C.A. Lowery, G.F. Kaufmann, K.D. Janda , J. Am. 
Chem Soc 2012, 134, 13562–13564 
 
[21] S. Stotani, V. Gatta, P. Medarametla, M Padmanaban, A. Karawajczyk, F. 
Giordanetto, P. Tammela, T. Laitinen, A. Poso, D. Tzalis, S. Collina, J 
Med Chem 2019, 62(5), 2720-2737. 
 
[22] P. Medarametla P, V. Gatta, T. Kajander, T. Laitinen, P. Tammela, A. Poso, 
ChemMedChem 2018, 13(22), 2400-2407. 
 
[23] V. Gatta, P. Ilina, A. Porter, S. McElroy, P. Tammela, Int J Mol Sci 2019, 
20(12), pii: E3112. 
 
[24] C.A. Lowery, J. Park, G.F. Kaufmann, K.D. Janda, J Am Chem Soc 2008, 
130(29), 9200–9201. 
 
[25] P. Ilina P, X. Ma, H.O. SintiM, P. Tammela, J Microbiol Methods 2018, 154, 
40-45. 
 
[26] N. Weiland-Brauer, N. Pinnow, R.A. Schmitz, Appl Environ Microbiol 2015, 
81(4), 1477–1489 
 
[27] M. Barančoková, D. Kikelj, J. Ilaš, Fut Med Chem 2018, 10(10), 1207–1227. 
 
[28] J. Shong, C.H. Collins, ACS Synth Biol 2013, 2(10), 568-575 
 
[29] T. Baba, T. Ara, M. Hasegawa, Y. Takai, Y. Okumura, M. Baba, K.A. 
Datsenko, M. Tomita, B.L. Wanner, H. Mori, Mol Syst Biol 2006, 2, 
2006.0008 
 
[30] K.B. Xavier, B.L. Bassler, J Bacteriol 2005, 187(1), 238-248 
 
[31] J. Inglese, R.L. Johnson, A. Simeonov, M. Xia, W. Zheng, C.P. Austin, D.S. 
Auld, Nat Chem Biol 2007, 3(8), 466-479 
 
[32] J. Ha, P. Hauk, K. Cho, Y. Eo, X. Ma, K. Stephens, S. Cha, M. Jeong, J. 
Suh, H.O. Sintim, W.E. Bentley, K. Ryu, Sci Adv 2018, 4(6), eaar7063. 
 
[33] V. Roy, J.A. Smith, J. Wang, J.E. Stewart, W.E. Bentley, H.O. Sintim, J Am 
Chem Soc 2010, 132(32), 11141-50.  
 
[34] L. Wang, Y. Hashimoto, C.Y. Tsao, J.J. Valdes, W.E. Bentley, J Bacteriol, 
2005, 187(6), 2066-2076. 
 
[35] P.C.D. Hawkins, A.G. Skillman, G.L. Warren,  B.A. Ellingson, M.T. Stahl,  J 
Chem Inf Model 2010, 50, 572-584 
 
[36] B.P. Kelley, S.P. Brown, G.L. Warren, S.W. Muchmore, J Chem Inf Model, 
2015, 55, 1771-1780 
 
[37] M. McGann, J Chem Inf Model 2011, 51, 578-596 
 
[38] M. McGann, J Comput Aided Mol Des 2012, 26, 897-906 
 

















This article is protected by copyright. All rights reserved.
FULL PAPER    












Exploring quorum sensing inhibition: Target- and bioreporter-based approaches were utilized in parallel to screen 91 compounds 
targeted to the ATP binding pocket of LsrK, a kinase that functions in the autoinducer-2 pathway. Six compounds active against LsrK 
inhibited also the QS activation in the novel E. coli JW5503 pET-Plsrlux bioreporter. In addition, the cell-based set up provided 18 





















































This article is protected by copyright. All rights reserved.
FULL PAPER    
For internal use, please do not delete. Submitted_Manuscript 
 




















This article is protected by copyright. All rights reserved.
